Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron's Eylea in Phase 3 Test
• In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. •